New schizophrenia drug could treat Alzheimer's disease
A new era in psychiatric medicine is suggested by the approval of innovative drugs, though not all trials yield positive results.
Revolutionary drug for schizophrenia wins US approval
KarXT represents a groundbreaking schizophrenia treatment with a unique mechanism of action that may improve patient outcomes and tolerability compared to existing therapies.
Safer Psychedelic Drugs May Be Coming
Psychedelics offer therapeutic potential for mental health, yet face challenges including safety concerns and regulatory hurdles that could be addressed through next-generation approaches.
Startups Are Biohacking Psychedelic Drugs to Make Sure You Never Have a Bad Trip Again
Pharmaceutical companies are developing next-generation psychedelics to serve as safer psychotherapy treatments, with promising early research on compounds like R-MDMA.
New schizophrenia drug could treat Alzheimer's disease
A new era in psychiatric medicine is suggested by the approval of innovative drugs, though not all trials yield positive results.
Revolutionary drug for schizophrenia wins US approval
KarXT represents a groundbreaking schizophrenia treatment with a unique mechanism of action that may improve patient outcomes and tolerability compared to existing therapies.
Safer Psychedelic Drugs May Be Coming
Psychedelics offer therapeutic potential for mental health, yet face challenges including safety concerns and regulatory hurdles that could be addressed through next-generation approaches.
Startups Are Biohacking Psychedelic Drugs to Make Sure You Never Have a Bad Trip Again
Pharmaceutical companies are developing next-generation psychedelics to serve as safer psychotherapy treatments, with promising early research on compounds like R-MDMA.
Coupling of unactivated alkyl electrophiles using frustrated ion pairs - Nature
Efficient construction of C-C bonds is essential in organic synthesis, with cross-electrophile coupling (XEC) reactions offering an innovative approach by avoiding organometallic reagents.
How to transform scientific discoveries into better treatments
Transforming scientific discoveries into effective treatments requires innovative collaboration across disciplines and sectors to address complex healthcare challenges.
Eli Lilly CEO's explains how failing fast leads to success
Eli Lilly's CEO emphasizes the balance of technical excellence and the human impact of pharmaceuticals in combating serious health issues.
How to transform scientific discoveries into better treatments
Transforming scientific discoveries into effective treatments requires innovative collaboration across disciplines and sectors to address complex healthcare challenges.
Eli Lilly CEO's explains how failing fast leads to success
Eli Lilly's CEO emphasizes the balance of technical excellence and the human impact of pharmaceuticals in combating serious health issues.
Which disease-modifying Alzheimer's drugs are the most promising?
The UK health watchdog has rejected two new Alzheimer's drugs due to concerns over their effectiveness and potential side effects.
PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
PharmAbcine is advancing monoclonal antibody therapy, significantly targeting diseases with high efficacy and low side effects.
How AI is being used to accelerate clinical trials
Computing power followed Moore's law, but drug development has its own pace with Eroom's law. Clinical trials are lengthy, costly, and only few drugs get approval in the end.
This 'super gonorrhoea' drug holds a lesson for avoiding microbial armageddon
New antibiotics and antifungal drugs show promise in fighting drug-resistant infections
Non-profit organizations play a crucial role in developing and bringing new drugs to the market
An Experimental Weight-Loss Drug Shows Lasting Results in Early Study
Amgen's experimental weight-loss shot, MariTide, appears to keep weight off even after patients stop taking it.
MariTide is an antibody-drug conjugate that blocks the GIP receptor and mimics a gut hormone called GLP-1.
Which disease-modifying Alzheimer's drugs are the most promising?
The UK health watchdog has rejected two new Alzheimer's drugs due to concerns over their effectiveness and potential side effects.
PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
PharmAbcine is advancing monoclonal antibody therapy, significantly targeting diseases with high efficacy and low side effects.
How AI is being used to accelerate clinical trials
Computing power followed Moore's law, but drug development has its own pace with Eroom's law. Clinical trials are lengthy, costly, and only few drugs get approval in the end.
This 'super gonorrhoea' drug holds a lesson for avoiding microbial armageddon
New antibiotics and antifungal drugs show promise in fighting drug-resistant infections
Non-profit organizations play a crucial role in developing and bringing new drugs to the market
An Experimental Weight-Loss Drug Shows Lasting Results in Early Study
Amgen's experimental weight-loss shot, MariTide, appears to keep weight off even after patients stop taking it.
MariTide is an antibody-drug conjugate that blocks the GIP receptor and mimics a gut hormone called GLP-1.
Activist hedge fund Starboard met with Pfizer last week. Here's what went down.
Starboard is advocating for increased accountability and improvements in Pfizer's operational and financial strategies. Smith highlights a poor return on investments.
Top Trends in the European Digital Health/AI Market | Data Matters Privacy Blog
Digital health technologies are rapidly transforming drug development and healthcare delivery, with strong growth despite regulatory challenges.
Partners in drug discovery: how to collaborate with non-governmental organizations
Biomedical discoveries should actively seek partnerships with NGOs to bring ideas to fruition.
Collaboration in scientific research can lead to rapid product development, as demonstrated during COVID-19.
Can Better Biotech Finally Replace Lab Animals?
Itzy Morales Pantoja transitioned from animal testing to developing lab-grown models to advance neurodegeneration research and reduce reliance on animal studies.
Alzheimer's scientist indicted for allegedly falsifying data in $16M scheme
An Alzheimer's researcher allegedly falsified data to secure $16 million in research funding for an Alzheimer's drug, raising doubts about the integrity of the research.
The investigation revealed long-standing and egregious misconduct in data management by the researcher, leading to questions about the authenticity of the work.
When Choosing What Diseases to Develop Drugs For, It All Comes Down to Funding
Funding drives research decisions
The Orphan Drug Act incentivized drug development for rare diseases
Alzheimer's scientist indicted for allegedly falsifying data in $16M scheme
An Alzheimer's researcher allegedly falsified data to secure $16 million in research funding for an Alzheimer's drug, raising doubts about the integrity of the research.
The investigation revealed long-standing and egregious misconduct in data management by the researcher, leading to questions about the authenticity of the work.
When Choosing What Diseases to Develop Drugs For, It All Comes Down to Funding
Funding drives research decisions
The Orphan Drug Act incentivized drug development for rare diseases
New era of medicine breaks through against the most aggressive lung cancer
New drugs offer hope for small cell lung cancer treatment.
Feinberg Scientists to Lead Grant Studying Autism, Schizophrenia - News Center
Northwestern Medicine secures $17 million grant to explore genetic causes of autism and schizophrenia for new drug development.
A disease-associated gene desert directs macrophage inflammation through ETS2 - Nature
Only 10% of drugs developed for autoimmune diseases are successful due to a lack of efficacy and poor understanding of disease mechanisms.
Ketamine for depression: slow-release pills could make treatment more accessible
Ketamine tablet could revolutionize depression treatment, offering a more convenient alternative to intravenous administration with reduced side effects.
The Next Potential Alzheimer's Drug Clears a Big Hurdle
Drug companies are making progress in Alzheimer's treatment with FDA panel's positive evaluation of Eli Lilly's donanemab.